Postsustained Virological Response Management in Hepatitis C Patients

Chiara Masetti; Ana Lleo; Matteo Colombo; Massimo Colombo; Alessio Aghemo

doi:10.1055/s-0040-1702944

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2020; 40(03): 233-239
DOI: 10.1055/s-0040-1702944

Review Article

Postsustained Virological Response Management in Hepatitis C Patients

Autor*innen

Chiara Masetti

¹Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy
Ana Lleo

¹Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy

²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
Matteo Colombo

¹Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy

²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
Massimo Colombo

¹Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy
Alessio Aghemo

¹Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy

²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

Abstract

The introduction of direct-acting antiviral agents (DAA) has revolutionized management and care of patients with chronic hepatitis C virus (HCV) infection, leading to cure rates higher than 90% in patients with advanced liver disease as well. Viral eradication has been associated with longer survival, reduced mortality from both hepatic and extrahepatic causes, improvement in liver function, and reduced incidence of HCV-related extrahepatic diseases. While patients with mild fibrosis can safely be discharged after achievement of a sustained virological response, patients with advanced fibrosis and cirrhosis remain at risk of developing complications of liver disease, thus requiring regular and life-long surveillance. Major complications of cirrhosis that need to be monitored are hepatocellular carcinoma onset and development or progression of clinically significant portal hypertension.

Keywords

HCV - SVR - complications

Volltext

Referenzen

References
1 WHO. Global Hepatitis Report, 2017. Available at: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ . Accessed February 19, 2020
2 Lee MH, Yang HI, Lu SN. , et al; R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206 (04) 469-477
3 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69 (02) 461-511
4 AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62 (03) 932-954
5 Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection. Ann Intern Med 2017; 166 (09) 637-648
6 Swain MG, Lai MY, Shiffman ML. , et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139 (05) 1593-1601
7 Hayashi K, Ishigami M, Ishizu Y. , et al. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. J Viral Hepat 2018; 25 (12) 1446-1451
8 Schwabe C, Lawitz EJ, Pol S, Shafran SD, Hyland R, Chen F. , et al. Sustained viral response following treatment with direct acting antiviral regimens is durable in more than 6,600 patients: results of the Gilead Sustained Virologic Response Registry Study. Hepatol 2018; 68 (s1): A595
9 Wei L, Huang HY. Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Rev Ant-Infect Ther 2019; 17 (Suppl. 05) 311-325
10 Midgard H, Weir A, Palmateer N. , et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol 2016; 65 (1, suppl): S33-S45
11 Berenguer J, Gil-Martin Á, Jarrin I. , et al; Madrid-CoRe Study Group. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals. AIDS 2019; 33 (04) 685-689
12 Bhandari R, Morey S, Hamoodi A. , et al. High rates of hepatitis C reinfection following antiviral treatment in the North East England prisons. J Viral Hepat 2019; (e-pub ahead of print)
13 Terrault NA. Care of patients following cure of hepatitis C virus infection. Gastroenterol Hepatol (N Y) 2018; 14 (11) 629-634
14 Ciancio A, Bosio R, Bo S. , et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol 2018; 90 (02) 320-327
15 Petta S, Adinolfi LE, Fracanzani AL. , et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018; 69 (01) 18-24
16 Cacoub P, Si Ahmed SN, Ferfar Y. , et al. Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis. Clin Gastroenterol Hepatol 2019; 17 (03) 518-526
17 Carrat F, Fontaine H, Dorival C. , et al; French ANRS CO22 Hepather Cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019; 393 (10179): 1453-1464
18 Nahon P, Bourcier V, Layese R. , et al; ANRS CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017; 152 (01) 142-156.e2
19 Cacoub P, Nahon P, Layese R. , et al; ANRS CO12 CirVir group. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. Am Heart J 2018; 198: 4-17
20 El-Serag HB, Christie IC, Puenpatom A, Castillo D, Kanwal F, Kramer JR. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther 2019; 49 (11) 1442-1447
21 Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat 2016; 23 (07) 536-544
22 Arcaini L, Besson C, Frigeni M. , et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 2016; 128 (21) 2527-2532
23 Bonacci M, Lens S, Mariño Z. , et al. Long term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterology 2018; 155 (02) 311-315.e6
24 Mahale P, Torres HA, Kramer JR. , et al. Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry-based case-control study. Cancer 2017; 123 (07) 1202-1211
25 Pol S, Vallet-Pichard A, Hermine O. Extrahepatic cancers and chronic HCV infection. Nat Rev Gastroenterol Hepatol 2018; 15 (05) 283-290
26 Nahon P, Bourcier V, Layese R. , et al; ANRS CO12 CirVir Group. Eradication of hepatitis C virus in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017; 152 (01) 142-156.e2
27 Allaire M, Nahon P, Layese R. , et al; ANRS CO12 CirVir Group. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Hepatology 2018; 68 (04) 1245-1259
28 Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology 2018; 68 (03) 827-838
29 Bruno S, Di Marco V, Iavarone M. , et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 2016; 64 (06) 1217-1223
30 Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M. ; collaborators. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig Liver Dis 2019; 51 (02) 310-317
31 Calvaruso V, Cabibbo G, Cacciola I. , et al; Rete Sicilia Selezione Terapia–HCV (RESIST-HCV). Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018; 155 (02) 411-421.e4
32 Degasperi E, D'Ambrosio R, Iavarone M. , et al. Factors associated with increased risk of de-novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol 2019; 17 (06) 1183-1191.e7
33 Walker AJ, Peacock CJ, Pedergnana V, Irving WL. STOP-HCV Consortium. Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review. J Viral Hepat 2018; 25 (05) 442-456
34 Nguyen K, Jimenez M, Moghadam N. , et al. Decrease of alpha-fetoprotein in patients with cirrhosis treated with direct-acting antivirals. J Clin Transl Hepatol 2017; 5 (01) 43-49
35 Masetti C, Lionetti R, Lupo M. , et al. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2018; 25 (12) 1493-1500
36 Conti F, Buonfiglioli F, Scuteri A. , et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65 (04) 727-733
37 Reig M, Mariño Z, Perelló C. , et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65 (04) 719-726
38 Lens S, Alvarado-Tapias E, Mariño Z. , et al. Effects of all-oral antiviral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 2017; 153 (05) 1273-1283.e1
39 Afdhal N, Everson GT, Calleja JL. , et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat 2017; 24 (10) 823-831
40 Di Marco V, Calvaruso V, Ferraro D. , et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stages of portal hypertension. Gastroenterology 2016; 151 (01) 130-139.e2
41 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
42 Thabut D, Bureau C, Layese R. , et al; ANRS CO12 CirVir group. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology 2019; 156 (04) 997-1009.e5
43 de Franchis R. The changing scenario of screening and surveillance of esophageal varices. Gastroenterology 2019; 156 (04) 864-866
44 Velosa J. Why is viral eradication so important in patients with HCV-related cirrhosis?. Antivir Ther 2017; 22 (01) 1-12
45 Romano J, Sims OT, Richman J. , et al. Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients. JGH Open 2018; 2 (06) 317-321
46 Gentile I, Scotto R, Coppola C. , et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int 2019; 13 (01) 66-74
47 Belli LS, Berenguer M, Cortesi PA. , et al; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016; 65 (03) 524-531
48 D'Ambrosio R, Aghemo A, Fraquelli M. , et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013; 59 (02) 251-256
49 D'Ambrosio R, Degasperi E, Aghemo A. , et al. Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon. PLoS One 2016; 11 (06) e0155967
50 Terrault NA, Hassanein TI. Management of the patient with SVR. J Hepatol 2016; 65 (1, suppl): S120-S129
51 Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol 2018; 24 (11) 1269-1277
52 Mauss S, Buendgens L, Christensen S. , et al. Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C. Z Gastroenterol 2019; 57 (02) 139-147
53 Spadaccini M, Lleo A, Ceriani R. , et al. Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. Hepatobiliary Pancreat Dis Int 2018; 17 (06) 570-574